German experts confirm that Cuban COVID-19 vaccines could be part of the continent’s immunogen portfolio
Cuban-made vaccines could form a vital part of the immunogen portfolio that the continent will need for many years to come, say eminent German professors Bert Hoffmann and Jan Felix Drexler, in the article “COVID-19 in Latin America: where we are and what is to come”
Translated and edited by Walter Lippmann for CubaNews.
Cuban-made vaccines can form a vital part of the immunogen portfolio that the continent will need for many years to come, say eminent German professors Bert Hoffmann and Jan Felix Drexler, in the article “COVID-19 in Latin America: where we are and what is to come”.
In the text published in the giga magazine of the German Institute for Global and Area Studies, both specialists agree that “given that vaccines are being produced in the region, their trade should be facilitated.
They also reflect on the vaccines that have been inoculated in the Latin American region. These include vectored vaccines such as those of AstraZeneca, Johnson & Johnson or Russia’s Sputnik-V; mRNA vaccines such as those of Pfizer/BioNTech and Moderna (a modified messenger RNA encoding the spike protein); inactivated vaccines such as SinoVac and Sinopharm (which rely on cultured SARS-COV-2 that is chemically inactivated, for example, with formaldehyde); and protein subunit-based vaccines such as Cuba, Abdala and Soberana (which rely on the spike protein receptor-binding domain, in the case of Soberana, coupled to tetanus toxoid to enhance immunogenicity).
“Moreover, Cuba’s vaccines are a different case, as they are not produced under license from international companies, but are original developments of the Island’s biotechnology sector, a remarkable achievement given the country’s economic limitations and the fact that much richer states and pharmaceutical companies did not achieve this,” they point out, elsewhere in the text.
“Cuba also became the first country in the world to vaccinate children over the age of two. By the end of 2021, it is likely that the island will have fully vaccinated 90% of its population,” they point out.
CUBA INTENSIFIES VACCINE PRODUCTION
Cuba reached 40 million doses of the anti-COVID-19 Abdala vaccine, an achievement reached by the shared effort and work of the Center for Genetic Engineering and Biotechnology (CIGB) and the AICA pharmaceutical laboratories, institutions that give prestige to Cuban science.
According to the Twitter account of AICA Laboratories, this result is the result of a common vision, and highlights the importance of teamwork between two entities of the business group of the Biotechnological and Pharmaceutical Industries of Cuba (BioCubaFarma).